Gainers
-
Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP) rose 87.2 percent to $10.95 in the pre-market trading after the company
reported positive topline results from Phase 2 study evaluating Resunab for the treatment of diffuse cutaneous systemic
sclerosis.
-
Eleven Biotherapeutics Inc (NASDAQ: EBIO) rose
27.9 percent to $3.35 in pre-market trading. Eleven Biotherapeutics posted Q3 earnings of $0.91 per diluted share on revenue of
$28.65 million.
-
Amaya Inc. (NASDAQ: AYA) shares rose 25 percent to
$17.00 in pre-market trading. Amaya posted upbeat Q3 earnings and issued a strong FY16 earnings forecast. Amaya’s former CEO,
David Baazov, offered to acquire the company in a deal valued at around C$3.48 billion, or $2.56 billion.
-
Harman International Industries Inc (NYSE: HAR)
shares rose 24.9 percent to $109.45 in pre-market trading after Samsung Electronics announced plans to buy the company in an $8
billion deal.
-
Digi International Inc. (NASDAQ: DGII) rose 22.8
percent to $14.30 in pre-market trading. Belden Inc. (NYSE: BDC) proposed to buy Digi International for $13.82 per share. However, Digi
International’s board confirmed the rejection of proposal from Belden.
-
Mentor Graphics Corp (NASDAQ: MENT) rose 19.4
percent to $36.64 in pre-market trading after Siemens announced plans to acquire the company for $37.25 per share in cash.
-
Tuniu Corp (NASDAQ: TOUR) rose 13.7 percent to
$9.90 in pre-market trading after gaining 0.35 percent on Friday.
-
Ocular Therapeutix Inc (NASDAQ: OCUL) shares rose
13.5 percent to $7.80 in pre-market trading after the company reported successful topline results for both inflammation and
pain primary efficacy endpoints from its Phase 3 clinical trial of DEXTENZA.
-
Mechel PAO (ADR) (NYSE: MTL) shares rose 13.4
percent to $6.18 in pre-market trading after dropping 3.20 percent on Friday
-
Archer Daniels Midland Company (NYSE: ADM) rose 8.9
percent to $45.45 in the pre-market trading session after dropping 7.64 percent on Friday.
-
PTC Therapeutics, Inc. (NASDAQ: PTCT) rose 8
percent to $12.20 in pre-market trading. Credit Suisse upgraded PTC Therapeutics from Neutral to Outperform and raised the
price target from $15.00 to $25.00.
Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep.
Losers
-
Dynavax Technologies Corporation (NASDAQ: DVAX)
shares fell 71.1 percent to $3.35 in pre-market trading following announcement of a Complete Response Letter from the FDA.
-
Resource Capital Corp. (NYSE: RSO) shares fell 26.2
percent to $8.98 in pre-market trading. Resource Capital reported Q3 funds from operations of $12.9 million, or $42 per share.
-
Galena Biopharma Inc (NASDAQ: GALE) fell 14.1
percent to $3.61 in pre-market trading after the company disclosed that data from GALE-301/GALE-302 clinical program was
presented at the Society for Immunotherapy of Cancer Conference 2016.
-
Central European Media Enterprises Ltd. (NASDAQ: CETV) shares fell 5.8 percent to $2.45 in the pre-market trading session after
gaining 4.00 percent on Monday.
-
Aecom (NYSE: ACM) fell 5.3 percent to $30.50 in
pre-market trading after the company posted downbeat Q4 results.
-
Petroleo Brasileiro SA Petrobras (ADR) (NYSE: PBR)
fell 5.1 percent to $9.23 in pre-market trading after dropping 5.90 percent on Friday.
-
Concordia International Corp (NASDAQ: CXRX)
shares fell 4.6 percent to $2.70 in pre-market trading after surging 25.78 percent on Friday.
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.